Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06439082 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06439082 · ClinicalTrials.gov record · last posted 2026-08-19

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

Study acronym: SPARKLE
StatusRecruiting
PhasePhase 3
Started2024-10-24
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises.

Protocol amendment history 3 changes detected by DataLookout

2026-07-25
Enrollment increased: 315 → 354 participants
2026-07-25
Primary completion pushed: 2029-03-23 → 2029-07-02
2026-07-25
Completion pushed: 2030-04-19 → 2030-07-29
Trial Details
NCT Number NCT06439082
Lead Sponsor Novartis Pharmaceuticals
Conditions Sickle Cell Disease
Enrollment 354 participants
Start Date 2024-10-24
Primary Completion 2029-07-02 (estimated)
Study Completion 2030-07-29 (estimated)
Updated on ClinicalTrials.gov 2026-08-19